<DOC>
	<DOCNO>NCT01004185</DOCNO>
	<brief_summary>The purpose study determine whether low dose Asacol® ( 27 mg/kg - 71 mg/kg ) high dose Asacol® ( 53 mg/kg - 118 mg/kg ) safe effective dose 400 mg delayed-release tablet give twice daily 26 week child adolescent maintenance remission ulcerative colitis .</brief_summary>
	<brief_title>Assessing Safety/Efficacy Asacol® Given Every 12 Hours Children Adolescents Maintenance Remission Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>male female age 5 17 year , inclusive , time first dose study medication ; document history UC successfully maintain complete remission least 1 month prior study entry baseline PUCAI score &lt; 10 body weight less 17 kg 90 kg history least 1 active episode relapse last 12 month take stable maintenance dose oral mesalamine ( equivalent oral 5ASA dose ) least 1 month prior entry study . Stable define dose last month . maintain complete remission , define , throughout 30day runin phase . Note : ONLY applies patient complete 6week treatment complete remission Study 2007017 immediately rollover 30day runin phase female patient premenarchal negative urine pregnancy test , sexually active , practice acceptable contraception ( e.g. , abstinence ; oral , intramuscular , implanted hormonal contraception [ least 3 month prior enrollment ] history allergy hypersensitivity salicylate , aminosalicylates , component Asacol tablet significant coexist illness condition ( ) , include limited cancer significant organic psychiatric disease medical history physical examination , , judgment Investigator , contraindicate ( ) administration study drug and/or study procedure history presence condition cause malabsorption effect gastrointestinal motility history extensive small bowel resection ( great one half length small intestine ) cause short bowel syndrome `` condition '' cause `` malabsorption '' effect gastrointestinal `` motility '' current renal disease , screen blood urea nitrogen ( BUN ) creatinine value &gt; 1.5 time upper limit age appropriate normal document history current hepatic disease , liver function test ( alanine transaminase [ ALT ] , aspartate transaminase [ AST ] , total bilirubin ) &gt; 2 time upper limit normal history pancreatitis undergone treatment oral , intravenous , intramuscular , rectally administer corticosteroid ( include budesonide ) within 30 day prior Screening visit undergone treatment rectal mesalamine therapy within 30 day prior screen visit undergone treatment immunomodulatory therapy include , limited : rosiglitazone , 6mercaptopurine azathioprine , cyclosporine , methotrexate within 90 day prior Screening visit undergone treatment biologic therapy include , limited : infliximab , adalimumab , certolizumab biologic treatment ulcerative colitis within 90 day prior Screening visit undergone treatment antibiotic ( topical antibiotic ) include metronidazole within 7 day prior Screening visit undergone treatment aspirin nonsteroidal antiinflammatory drug NSAIDs ) within 7 day prior Screening visit undergone treatment antidiarrheal and/or antispasmodic within 30 day Screening visit stool examination positive Clostridium difficile ( C. difficile ) , bacterial pathogen , ova parasite . Note : Because normal gut flora may vary geography , Medical Monitor consult exclude patient stool sample positive C. difficile , bacterial pathogen ova parasite .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>